Anogenital Venereal Wart disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ANG005 MIFTS: 56	Anogenital Venereal Wart Categories: Infectious diseases, Oral diseases, Reproductive diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Anogenital Venereal Wart

MalaCards integrated aliases for Anogenital Venereal Wart:

Name: Anogenital Venereal Wart ¹¹ ¹⁴ ¹⁶

Genital Warts ¹¹ ⁵³ ⁴¹ ² ¹⁴ ³³

Condylomata Acuminata ⁴³ ⁷¹ ³³

Condyloma Acuminatum ¹¹ ⁷⁵

Anogenital Warts ¹¹ ³³

Anogenital Human Papilloma Virus Infectious Disease ¹¹

Genital Wart Virus Infectious Disease ¹¹

Verrucae Anogenitales ³³

Verrucae Genitales ³³

Venereal Warts ³³

Venereal Wart ¹¹

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases Reproductive diseases Oral diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain infectious and parasitic diseases

Infections with a predominantly sexual mode of transmission

Other predominantly sexually transmitted diseases, not elsewhere classified

Anogenital (venereal) warts

ICD11: ³³

Certain infectious or parasitic diseases

Predominantly sexually transmitted infections

Anogenital warts

Genital warts

External Ids:

Disease Ontology ¹¹ DOID:11168

ICD9CM ³⁴ 078.11

MeSH ⁴³ D003218

NCIt ⁴⁹ C2960 C4820

SNOMED-CT ⁶⁸ 240542006 302812006

ICD10 ³¹ A63.0

EFO ¹⁶ EFO_0007147

ICD11 ³³ 144526718 641342831

UMLS ⁷¹ C0009663 C0554632

Sources

Summaries for Anogenital Venereal Wart

MedlinePlus: ⁴¹ Genital warts are a sexually transmitted disease (STD) caused by the human papillomavirus (HPV). The warts usually appear as a small bump or group of bumps in the genital area. They are flesh-colored and can be flat or look bumpy like cauliflower. Some genital warts are so small you cannot see them. In women, the warts usually occur in or around the vagina, on the cervix, or around the anus. In men, genital warts are less common. They may have warts on the tip of the penis, around the anus, or on the scrotum, thigh, or groin. You can get genital warts during oral, vaginal, or anal sex with an infected partner. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading HPV. If your or your partner is allergic to latex, you can use polyurethane condoms. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. HPV vaccines may help prevent some of the HPV infections that cause genital warts. Your health care provider usually diagnoses genital warts by seeing them. The warts might disappear on their own. If not, your health care provider can treat or remove them. HPV stays in your body even after treatment, so warts can come back. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary: Anogenital Venereal Wart, also known as genital warts, is related to verrucous carcinoma and papilloma, and has symptoms including anogenital warts, fever and pruritus. An important gene associated with Anogenital Venereal Wart is IFNA1 (Interferon Alpha 1), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Imiquimod and Cantharidin have been mentioned in the context of this disorder. Affiliated tissues include skin of vagina, cervix and skin, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology: ¹¹ A viral infectious disease that results in infection located in skin of vagina, cervix, uterus, anus, penis, scrotum, mouth, or throat, has material basis in human papillomaviruses (types 6 and 11), which are transmitted by direct contact with the skin during oral, genital, or anal sex with an infected partner. The infection has symptom anogenital warts.

CDC: ² HPV is a common virus that can lead to certain types of cancer later in life. Getting your 11-12 year-old child two doses of the HPV vaccine can prevent these cancers.

Wikipedia: ⁷⁵ Genital warts are a sexually transmitted infection caused by certain types of human papillomavirus... more...

Sources

Related Diseases for Anogenital Venereal Wart

Diseases related to Anogenital Venereal Wart via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 704)

#	Related Disease	Score	Top Affiliating Genes
1	verrucous carcinoma	31.3	TP53 GP5 CDKN2A
2	papilloma	31.3	UBE3A TP53 CDKN2A CCR6
3	syphilis	30.9	CD8A CD4 CCR6
4	common wart	30.9	TP53 TMC8 TLR7 IFNA1 CD4
5	squamous cell papilloma	30.8	TP53 GP5 CDKN2A
6	keratosis, seborrheic	30.6	TP53 TMC8 CDKN2A
7	inflammatory bowel disease 1	30.6	TLR4 H2AC18 CCR6
8	primary syphilis	30.6	CD8A CD4
9	penile benign neoplasm	30.5	TP53 GP5 CDKN2A
10	phimosis	30.5	TP53 GP5 CDKN2A
11	vulva squamous cell carcinoma	30.5	TP53 GP5 CDKN2A
12	autoimmune polyendocrine syndrome	30.5	IFNA1 CD4 CCR6
13	adenocarcinoma in situ	30.5	TP53 GP5 CDKN2A
14	anal squamous cell carcinoma	30.5	TP53 H2AC18 CDKN2A CD8A CD4
15	molluscum contagiosum	30.5	TLR9 TLR3 IFNB1
16	lichen sclerosus et atrophicus	30.5	TLR4 CD8A
17	panniculitis	30.4	CD8A CD4 CCR6
18	croup	30.4	IFNB1 IFNA1 CD4
19	acanthoma	30.4	TP53 TMC8 CDKN2A
20	suppressor of tumorigenicity 3	30.4	UBE3A TP53 CDKN2A
21	urethritis	30.4	TLR4 CD8A CD4
22	chronic cervicitis	30.4	TP53 GP6 GP5 CDKN2A
23	vulva cancer	30.4	TP53 GP5 CDKN2A
24	focal epithelial hyperplasia	30.3	TP53 TMC8 GP6 GP5
25	mumps	30.3	TLR3 IL2 IFNB1 IFNA1
26	vulvar disease	30.3	TP53 GP5 CDKN2A
27	scabies	30.3	CD8A CD4 CCR6
28	urinary tract infection	30.3	TLR4 H2AC18 CD4 CCR6
29	herpes simplex	30.3	TLR9 TLR3 IFNB1 IFNA1 CD8A
30	cellulitis	30.3	CD8A CD4 CCR6
31	vitiligo-associated multiple autoimmune disease susceptibility 1	30.3	IL2 CD8A CD4 CCR6
32	hepatitis a	30.3	TLR4 TLR3 IFNA1 CD4
33	panuveitis	30.3	CD8A CD4 CCR6
34	lymphangioma	30.2	TP53 H2AC18 CD8A CD4 CCR6
35	vaginitis	30.2	TLR4 CD4 CCR6
36	rubella	30.2	TLR4 TLR3 IL2 IFNB1
37	penile cancer	30.2	UBE3A TP53 GP6 GP5 CDKN2A CD8A
38	head and neck cancer	30.2	TP53 H2AC18 CDKN2A CD8A CD4 CCR6
39	cervix uteri carcinoma in situ	30.2	TP53 GP6 GP5 CDKN2A CD4
40	lymphoma, hodgkin, classic	30.2	TP53 IL2 H2AC18 CCR6
41	acquired immunodeficiency syndrome	30.1	TP53 NCR1 IL2 IFNA1 CD4
42	basal cell carcinoma	30.1	TP53 TLR7 H2AC18 CDKN2A CCR6
43	vaginal cancer	30.1	UBE3A TP53 GP5 CDKN2A CD8A CD4
44	deficiency anemia	30.1	TP53 IL2 IFNA1 H2AC18 CD8A CD4
45	colitis	30.1	TLR9 TLR4 IL2 CD4 CCR6
46	contact dermatitis	30.0	IL2 CD8A CD4 CCR6
47	systemic scleroderma	30.0	IL2 IFNA1 H2AC18 CD8A CD4 CCR6
48	myelodysplastic syndrome	30.0	TP53 H2AC18 CDKN2A CD8A CD4 CCR6
49	vaccinia	30.0	TP53 IL2 IFNB1 IFNA1
50	poliomyelitis	29.9	TLR3 IL2 IFNB1 IFNA1 CD8A CD4

Graphical network of the top 20 diseases related to Anogenital Venereal Wart:

Sources

Symptoms & Phenotypes for Anogenital Venereal Wart

Symptoms:

¹¹

• anogenital warts

UMLS symptoms related to Anogenital Venereal Wart:

fever; pruritus; pelvic pain; penile warts

GenomeRNAi Phenotypes related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.14	CCR6 CD4 CD8A CDKN2A GP5 GP6
2	no effect	GR00402-S-2	10.14	CCR6 CD4 CDKN2A GP5 GP6 H2AC18

MGI Mouse Phenotypes related to Anogenital Venereal Wart:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.16	CCR6 CD4 CDKN2A GP5 GP6 IFNB1
2	immune system	MP:0005387	10.09	CCR6 CD4 CD8A CDKN2A GP6 IFNA1
3	normal	MP:0002873	9.97	CCR6 CD8A GP5 IFNA1 IFNA6 IFNB1
4	neoplasm	MP:0002006	9.91	CDKN2A IFNB1 IL2 TLR3 TLR4 TLR7
5	hematopoietic system	MP:0005397	9.58	CCR6 CD4 CD8A CDKN2A GP6 IFNA1
6	respiratory system	MP:0005388	9.56	CDKN2A IFNA1 IFNA6 IL2 TLR3 TLR4

Sources

Drugs & Therapeutics for Anogenital Venereal Wart

Drugs for Anogenital Venereal Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Imiquimod

Approved, Investigational

Phase 4

99011-02-6

57469

Cantharidin

Approved, Investigational

Phase 4

56-25-7

2545

Cianidanol

Approved, Withdrawn

Phase 4

154-23-4

9064

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Epicatechin

Investigational

Phase 4

490-46-0

58571364 72276

Tea

Phase 4

Adjuvants, Immunologic

Phase 4

Podophyllin

Approved

Phase 3

9000-55-9

Petrolatum

Approved, Investigational

Phase 3

8009-03-8

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Picropodophyllin

Approved, Investigational

Phase 3

518-28-5, 477-47-4

10607 72435

Insulin, Globin Zinc

Phase 3

Insulin

Phase 3

Keratolytic Agents

Phase 3

Dermatologic Agents

Phase 3

Antiviral Agents

Phase 3

Anti-Infective Agents

Phase 3

interferons

Phase 3

Antirheumatic Agents

Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Immunosuppressive Agents

Phase 3

Interferon-gamma

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Immunologic Factors

Phase 3

Vaccines

Phase 3

Nitric Oxide

Approved

Phase 2

10102-43-9

145068

Sodium citrate

Approved, Investigational

Phase 2

68-04-2

23431961

Coal tar

Approved

Phase 2

8007-45-2

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 2

77-92-9

311

Ranpirnase

Investigational

Phase 1, Phase 2

196488-72-9

Ammonium trichloro(dioxoethylene-O,O'-)tellurate

Phase 1, Phase 2

Radiation-Protective Agents

Phase 1, Phase 2

Reverse Transcriptase Inhibitors

Phase 1, Phase 2

Protective Agents

Phase 1, Phase 2

Pharmaceutical Solutions

Phase 1, Phase 2

Calcium, Dietary

Phase 2

Anticoagulants

Phase 2

Citrate

Phase 2

Chelating Agents

Phase 2

Calcium

Nutraceutical

Phase 2

7440-70-2

271

Cidofovir

Approved

Phase 1

113852-37-2

60613

Aminolevulinic acid

Approved

106-60-5

137

Formaldehyde

Approved, Vet_approved

50-00-0

712

Ethanol

Approved

64-17-5

702

Photosensitizing Agents

Contraceptive Agents

Interleukin-4

Anti-Infective Agents, Local

Interventional clinical trials:

(show top 50) (show all 99)

#	Name	Status	NCT ID	Phase	Drugs
1	Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts	Completed	NCT00189293	Phase 4	Imiquimod
2	Alternate Dosing Schedules Study for HPV Vaccine	Completed	NCT00862810	Phase 4
3	An Open-Label, Single-Center Phase I (Phase IV/ USA) Study to Assess the Pharmacokinetic Profile of Topically Applied Veregen® 15% in Patients With External Genital and Perianal Warts Compared With Oral Intake of a Green Tea Beverage	Completed	NCT01082302	Phase 4	Polyphenon E (Veregen) 15% ointment
4	Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts	Completed	NCT03625960	Phase 4	Cantharidin;Trichloroacetic Acid
5	A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts	Terminated	NCT01468636	Phase 4	Oral Zinc;Placebo
6	The Efficacy of Intralesional Measles, Mumps, Rubella (MMR) Vaccine, Intralesional Candidal Antigen and Topical Podophyllin in Treatment of Genital Warts: A Comparative Study	Unknown status	NCT03853785	Phase 3	Topical Podophyllin
7	Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place	Unknown status	NCT03296397	Phase 3
8	Betaglucin 0.2% Gel Versus Imiquimod Cream 5% in the Treatment of Anogenital Warts in 102 Individuals Older Than 18 Years.	Unknown status	NCT03901690	Phase 3	Betaglucin soluble gel 0.2%;Imiquimod 5% cream
9	Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients	Unknown status	NCT03153566	Phase 3
10	A Randomized, Double-Blind, Three-Arm Parallel-Group, Placebo-Controlled Phase 3 Trial to Investigate the Clinical Efficacy and Safety of Polyphenon E in the Treatment of External Genital Warts	Completed	NCT00449982	Phase 3	Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
11	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts	Completed	NCT00674739	Phase 3	Imiquimod;3.75% imiquimod cream;placebo cream
12	A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts	Completed	NCT00735462	Phase 3	2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
13	A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women	Completed	NCT00092521	Phase 3
14	Phase III Study of the Treatment of Genital Warts by Low Dose Cyclophosphamide	Completed	NCT00999986	Phase 3	cyclophosphamide
15	Immunogenicity and Safety of Quadrivalent HPV L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women When Administered Alone or Concomitantly With Hepatitis B Vaccine (Recombinant)--the F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease	Completed	NCT00517309	Phase 3
16	A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine	Completed	NCT00501137	Phase 3
17	A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women	Completed	NCT00543543	Phase 3
18	A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine	Completed	NCT00092495	Phase 3
19	A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women	Completed	NCT01651949	Phase 3
20	A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™	Completed	NCT01047345	Phase 3
21	An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds)	Completed	NCT03158220	Phase 3
22	Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)	Completed	NCT00092482	Phase 3
23	An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men	Completed	NCT00090285	Phase 3
24	A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam	Completed	NCT03546842	Phase 3
25	Open Controlled Randomized Study of the Efficacy and Safety of Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts (Phase III)	Completed	NCT05156541	Phase 3	Interferon gamma human recombinant (IFN-G)
26	A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Study of Hyloris Developments' Podofilox Topical Gel 0.5% Compared to Allergan's Condylox® Gel 0.5% in Male and Female Patients With External Anogenital Warts.	Completed	NCT03532776	Phase 3	Podofilox Gel 0.5%;Condylox Topical Gel 0.5%;Placebo Gel
27	A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years	Completed	NCT04425291	Phase 3
28	Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents.	Completed	NCT01111344	Phase 3
29	A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years	Completed	NCT05372016	Phase 3
30	Prophylactic Vaccines as Therapy: Prevention of Recurrence of Extensive Genital Warts	Recruiting	NCT02750202	Phase 3
31	A Phase 3 Open-Label Immunogenicity and Safety Study of 2-Dose Regimens of V503, a 9-Valent Human Papillomavirus (HPV) Vaccine in Chinese Males 9 Through 14 Years Old and 3-Dose Regimen of V503 in Chinese Males 9 Through 19 Years Old	Recruiting	NCT05314023	Phase 3
32	Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial	Recruiting	NCT04895020	Phase 3
33	A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years	Recruiting	NCT04422366	Phase 3
34	Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial	Recruiting	NCT05027776	Phase 3
35	A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)	Active, not recruiting	NCT00092534	Phase 3
36	A Randomized, Single-blind Study to Compare Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) (Xiamen Innovax Biotech Co.,Ltd.) Versus Gardasil®9 (Merck & Co., Inc.) in Healthy Females 18-26 Years of Age	Active, not recruiting	NCT04782895	Phase 3
37	Immunogenicity Non-inferiority Immuno-bridging Study of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine (E.Coli) in Healthy Population Aged 9-17 Years Old vs Aged 18-26 Years Old	Active, not recruiting	NCT05056402	Phase 3
38	A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years	Active, not recruiting	NCT04537156	Phase 3
39	A Phase III, Randomized, Blinded, Positive-controlled Study to Compare the Immunogenicity of Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris) in Healthy Female Subjects Aged 16-26 Years.	Active, not recruiting	NCT05580341	Phase 3
40	A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age.	Active, not recruiting	NCT04635423	Phase 3
41	A Multicenter,Randomized, Placebo-Controlled, and Double-blind Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Aged 18-45 Years	Not yet recruiting	NCT05584332	Phase 3
42	Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma	Terminated	NCT01639638	Phase 2, Phase 3	PROAPOPTOTIC PEPTIDE CIGB 300
43	A Phase II, Multicenter, Randomized, Double Blind, Vehicle Controlled Study Evaluating the Efficacy and Tolerability of AS101 15% Gel for External Genital Warts.	Unknown status	NCT01943630	Phase 2	15% AS101 gel;Vehicle
44	A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts	Completed	NCT02462187	Phase 2	NVN1000 8% Gel;NVN1000 16%;Vehicle;NVN1000 24%
45	Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV	Completed	NCT02535104	Phase 1, Phase 2	Ranpirnase;Vehicle
46	A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs)	Completed	NCT02482428	Phase 2	Investigational Treatment;Aldara
47	A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts	Completed	NCT03981822	Phase 2
48	A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs)	Completed	NCT01796821	Phase 2	Vehicle gel;SR-T100 gel with 1.0 % SM;SR-T100 gel with 2.3% SM
49	A Phase I/II, Open Labeled, Uncontrolled, Single Center Study of Topical AS101 for External Genital Warts	Completed	NCT01555112	Phase 1, Phase 2	Topical AS101
50	A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group Study to Explore the Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts	Completed	NCT02849262	Phase 2	Omiganan (CLS001) topical gel;Vehicle topical gel

Search NIH Clinical Center for Anogenital Venereal Wart

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

imiquimod

Interferon Alfa-2b

Interferon Alfa-n3

podophyllin

PODOPHYLLIN PWDR

Cochrane evidence based reviews: condylomata acuminata

Sources

Genetic Tests for Anogenital Venereal Wart

Sources

Anatomical Context for Anogenital Venereal Wart

Organs/tissues related to Anogenital Venereal Wart:

FMA: Skin Of Vagina

MalaCards : Cervix, Skin, Uterus, T Cells, Thymus, Bone Marrow, Tongue

Sources

Publications for Anogenital Venereal Wart

Articles related to Anogenital Venereal Wart:

(show top 50) (show all 5024)

#	Title	Authors	PMID	Year
1	Immunothrombotic Mechanisms Induced by Ingenol Mebutate Lead to Rapid Necrosis and Clearance of Anogenital Warts. ⁶² ⁴¹	Braun SA...Homey B	36362165	2022
2	Establishing a prediction model for recurrence of condyloma acuminatum. ⁶² ⁴¹	Zhan M...Yang Y	36138469	2022
3	University Students' Knowledge about the Relation between Human Papillomavirus (HPV) and Head and Neck and Oral Cancers. ⁶² ⁴¹	Vieira VK...Lucio LC	36037126	2022
4	Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha. ⁵³ ⁶²	Foldvari M...King M	10512792	1999
5	Therapeutic approaches to papillomavirus infections. ⁵³ ⁶²	Baker GE...Tyring SK	9098642	1997
6	Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions. ⁵³ ⁶²	Arany I...Tyring SK	8946632	1996
7	Response to interferon treatment decreases with epidermal dedifferentiation in condylomas. ⁵³ ⁶²	Arany I...Tyring SK	8863992	1996
8	Intralesional beta-interferon treatment of cervical intraepithelial neoplasia associated with human papillomavirus infection. ⁵³ ⁶²	Penna C...Marchionni M	8016908	1994
9	[Interferons, a class of cytokines with a large therapeutic activity range]. ⁵³ ⁶²	Billard C	7515733	1993
10	A Rare Case of Vulvar Myiasis in a Mentally Subnormal Young Woman. ⁶²	George MC...Shrivastava S	36457453	2022
11	Role of chemokines in HPV-induced cancers. ⁶²	Israr M...Bonagura VR	36402301	2022
12	--Human papillomavirus and Chinese international students in the United States: attitudes, knowledge, vaccination trends, healthcare behaviors, and sexual activity. ⁶²	Esagoff A...Van Orman S	33705223	2022
13	Human Papillomavirus, Related Diseases, and Vaccination: Knowledge and Awareness Among Health Care Students and Professionals in Nepal. ⁶²	Suhaila K...Shrestha S	33939117	2022
14	Condyloma acuminatum of the urinary bladder with underlying squamous cell carcinoma: a case report. ⁶²	Whitaker JA	36457102	2022
15	Bleomycin-based electrochemotherapy for the treatment of a Buschke-Löwenstein tumor (perianal giant condyloma) in an HIV-positive kidney transplant recipient: A case report. ⁶²	Russano F...Alaibac M	36406182	2022
16	Squamous Cell Carcinoma Arising from Perianal Buschke-Lowenstein Tumor (Giant Condyloma Acuminatum): Comprehensive Literature Review. ⁶²	Ates M...Sarici KB	34694593	2022
17	Human papillomavirus infections in low-grade squamous intraepithelial lesion in Peruvian pregnant woman: A cross-sectional cytology-based study. ⁶²	Moya-Salazar J...Contreras-Pulache H	36381406	2022
18	Development of field-applicable endogenous internally controlled recombinase-aided amplification (EIC-RAA) assays for the detection of human papillomavirus genotypes 6 and 11 using sample releasing agent. ⁶²	He A...Ma X	36387484	2022
19	Human Papillomavirus E1 Protein Regulates Gene Expression in Cells Involved in Immune Response. ⁶²	Wang Z...Li Q	36418714	2022
20	Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain. ⁶²	Linertova R...Teljeur C	36347243	2022
21	Anal Human Papillomavirus Infection in Kidney Transplant Recipients Compared With Immunocompetent Controls. ⁶²	Larsen HK...Thomsen LT	35438132	2022
22	Photodynamic therapy in the treatment of condyloma acuminata: A systematic review of clinical trials. ⁶²	Prayogo SA...Intaran KDA	36420589	2022
23	Stated preferences for human papillomavirus vaccination for adolescents in selected communities in Ibadan, Southwest Nigeria: A discrete choice experiment. ⁶²	Balogun FM...Svensson M	36383765	2022
24	Alteration of Na/H exchange regulatory factor-1 protein levels in anogenital lesions positive for mucosal high-risk human papillomavirus type 16. ⁶²	Saponaro C...Tommasino M	36179457	2022
25	Intralesional immunotherapy for non-genital warts: A systematic review and meta-analysis. ⁶²	Ju HJ...Lee JH	35962514	2022
26	Health associations for male survivors of unwanted and non-consensual sex. ⁶²	Aiken J...Griner SB	34467798	2022
27	Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial. ⁶²	Shu Y...Zhang J	36283897	2022
28	Coexistence of condyloma acuminatum and extramammary Paget's disease on penis and scrotum: A rare case report. ⁶²	Kang I...Jung GY	36397375	2022
29	High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts. ⁶²	Nofal A...El-Hawary EE	36346210	2022
30	The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan. ⁶²	Chou HH...Chang CJ	36116338	2022
31	Could the human papillomavirus recombinant vaccine be a new valid approach in the management of ano-genital warts? ⁶²	Sarro A...Pecere A	34904623	2022
32	Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years. ⁶²	Maldonado I...Buchwald UK	35853188	2022
33	Topical hydrogen peroxide solution 40% in treatment of plane wart. ⁶²	Nouh EAR...Aboelwafa HO	35064617	2022
34	Changes in the Prevalence of Human Papillomavirus Genotypes in Genital Warts Since the Introduction of Prophylactic Vaccines. ⁶²	Magdaleno-Tapial J...Perez-Ferriols A	35688211	2022
35	Intralesional injection of purified protein derivative versus Candida antigen in treatment of genital warts. ⁶²	Tawfik NZ...Halim HM	36056784	2022
36	A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer. ⁶²	Faber MT...Kjaer SK	35657350	2022
37	Pemphigus vegetans misdiagnosed as condylomata acuminata: A case report. ⁶²	Siadat AH...Shahriarirad R	36258762	2022
38	Vaccination with human alphapapillomavirus-derived L2 multimer protects against human betapapillomavirus challenge, including in epidermodysplasia verruciformis model mice. ⁶²	Olczak P...Roden R	36070626	2022
39	Ten-Year Trend in Emergency Department Visits for Sexually Transmitted Infections among Adolescents: A Retrospective Cross-Sectional Study in Italy. ⁶²	Viottini E...Borraccino A	36361087	2022
40	Development and psychometric properties of the human papillomavirus-quality of life (HPV-QoL) questionnaire to assess the impact of HPV on women health-related-quality-of-life. ⁶²	Coronado PJ...Rejas-Gutierrez J	35551456	2022
41	Destructive therapies for cutaneous warts: A review of the evidence. ⁶²	Truong K...Wain T	36184865	2022
42	Successfully treated urethral condyloma acuminatum utilizing intraurethral self-application of 5-fluorouracil via Q-tip. ⁶²	Zillioux J...Goldman HB	36245207	2022
43	Factors affecting children's HPV vaccination in Austria: Evidence from a parent survey. ⁶²	Waser M...Borena W	36251011	2022
44	Condyloma acuminatum of the urinary tract demonstrates atypical squamous cells in urine cytology. ⁶²	Velez Torres JM...Kryvenko ON	36244465	2022
45	Recurrent condyloma acuminatum after cryotherapy plus photodynamic therapy successfully treated by local hyperthermia: A case report. ⁶²	Wang HF...Gao XH	35975429	2022
46	A new option for the treatment of condyloma acuminatum in the male urethra: Multimodal ultrasound image-guided scraping and photodynamic therapy (USP). ⁶²	Bu Z...Ali K	35753674	2022
47	ALA-PDT combined with oral acitretin in the treatment of refractory condyloma acuminatum in anal canal. ⁶²	Zhang L...Cheng Q	36183481	2022
48	Cryotherapy combined with photodynamic therapy for successful treatment of condyloma acuminatum in special sites such as the nipple and the nasal vestibule: A series of two case reports. ⁶²	Ye E...Bu Z	35644347	2022
49	Peripheral blood CD4+ T cell count predicts recurrence of condyloma acuminatum after photodynamic therapy in HIV-positive patients. ⁶²	Gu L...Hua H	36052757	2022
50	Umbilical giant condyloma acuminatum. ⁶²	D'Erme AM...Bagnoni G	34706983	2022

Sources

Genes for Anogenital Venereal Wart

Genes related to Anogenital Venereal Wart (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	IFNA1	Interferon Alpha 1	Protein Coding	12.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9342473 8863992 1723372 (more) 7515733 9098642 8016908 8946632 10512792
2	NCR1	Natural Cytotoxicity Triggering Receptor 1	Protein Coding	12.09	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
3	IFNA6	Interferon Alpha 6	Protein Coding	8.57	GeneCards inferred via : Summaries (show sections)
4	TLR7	Toll Like Receptor 7	Protein Coding	7.72	DISEASES inferred ¹⁴
5	CD4	CD4 Molecule	Protein Coding	7.06	DISEASES inferred ¹⁴
6	GP5	Glycoprotein V Platelet	Protein Coding	7.03	DISEASES inferred ¹⁴
7	TLR8	Toll Like Receptor 8	Protein Coding	6.71	DISEASES inferred ¹⁴
8	TLR9	Toll Like Receptor 9	Protein Coding	6.48	DISEASES inferred ¹⁴
9	CD8A	CD8a Molecule	Protein Coding	6.39	DISEASES inferred ¹⁴
10	TP53	Tumor Protein P53	Protein Coding	6.29	DISEASES inferred ¹⁴
11	H2AC18	H2A Clustered Histone 18	Protein Coding	6.26	DISEASES inferred ¹⁴ ¹⁴
12	UBE3A	Ubiquitin Protein Ligase E3A	Protein Coding	6.18	DISEASES inferred ¹⁴
13	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	6.16	DISEASES inferred ¹⁴
14	GP6	Glycoprotein VI Platelet	Protein Coding	6.1	DISEASES inferred ¹⁴
15	TLR3	Toll Like Receptor 3	Protein Coding	6.06	DISEASES inferred ¹⁴
16	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	5.92	DISEASES inferred ¹⁴ ¹⁴
17	TLR4	Toll Like Receptor 4	Protein Coding	5.85	DISEASES inferred ¹⁴
18	TMC8	Transmembrane Channel Like 8	Protein Coding	5.83	DISEASES inferred ¹⁴
19	IFNB1	Interferon Beta 1	Protein Coding	5.78	DISEASES inferred ¹⁴
20	IL2	Interleukin 2	Protein Coding	5.75	DISEASES inferred ¹⁴
21	TNF	Tumor Necrosis Factor	Protein Coding	5.74	DISEASES inferred ¹⁴
22	IFNA2	Interferon Alpha 2	Protein Coding	5.71	DISEASES inferred ¹⁴
23	RB1	RB Transcriptional Corepressor 1	Protein Coding	5.69	DISEASES inferred ¹⁴
24	IL6	Interleukin 6	Protein Coding	5.57	DISEASES inferred ¹⁴
25	TLR5	Toll Like Receptor 5	Protein Coding	5.52	DISEASES inferred ¹⁴
26	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	5.5	DISEASES inferred ¹⁴
27	TLR2	Toll Like Receptor 2	Protein Coding	5.49	DISEASES inferred ¹⁴

Sources

Variations for Anogenital Venereal Wart

Sources

Expression for Anogenital Venereal Wart

Search GEO for disease gene expression data for Anogenital Venereal Wart.

Sources

Pathways for Anogenital Venereal Wart

Pathways related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

(show all 39)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.8	UBE3A TP53 TLR9 TLR8 TLR7 TLR4
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.74	CD4 CDKN2A GP5 H2AC18 IFNA1 IFNA6
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.59	CCR6 CD4 IFNA1 IFNA6 IFNB1 IL2
4	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.44	TP53 TLR9 TLR8 TLR7 TLR4 TLR3
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.38	TP53 TLR9 TLR8 TLR7 TLR4 TLR3
6	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.92	TP53 TLR4 IL2 IFNB1 IFNA6 IFNA1
7	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.69	IL2 TLR3 TLR4 TLR7 TLR8 TLR9
8	TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions ⁶⁵ Show member pathways 14-3-3 Induced Apoptosis ⁶⁴ TNF Superfamily Pathway ⁶⁴ TNFs bind their physiological receptors ⁶⁶ TRAF Pathway ⁶⁴	12.59	TLR3 TLR4 TLR7 TLR8 TLR9
9	NF-kappaB Signaling ³	12.54	TLR9 TLR8 TLR7 TLR3 IL2 IFNA1
10	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.45	IFNA1 IFNB1 TLR3 TLR4 TLR7 TLR8
11	DDX58/IFIH1-mediated induction of interferon-alpha/beta ⁶⁶ Show member pathways Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Negative regulators of DDX58/IFIH1 signaling ⁶⁶ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁶ Novel intracellular components of RIG-I-like receptor pathway ⁷⁴ SARS-CoV-2 B.1.1.7 variant antagonises innate immune activation ⁷⁴ TRAF3-dependent IRF activation pathway ⁶⁶ TRAF6 mediated IRF7 activation ⁶⁶	12.43	TLR4 TLR3 IFNB1 IFNA6 IFNA1
12	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.41	TLR9 TLR8 TLR7 TLR4 TLR3
13	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.39	TLR9 TLR8 TLR7 TLR4 IFNB1
14	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.38	TP53 TLR9 TLR8 TLR7 TLR4 TLR3
15	Cytosolic sensors of pathogen-associated DNA ⁶⁶ Show member pathways Cytosolic DNA-sensing pathway ⁷⁴ DEx/H-box helicases activate type I IFN and inflammatory cytokines production ⁶⁶ IkBA variant leads to EDA-ID ⁶⁶ IRF3 mediated activation of type 1 IFN ⁶⁶ IRF3-mediated induction of type I IFN ⁶⁶ LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production ⁶⁶ Regulation by TREX1 ⁶⁶ Regulation of innate immune responses to cytosolic DNA ⁶⁶ RIP-mediated NFkB activation via ZBP1 ⁶⁶ Selenium micronutrient network ⁷⁴ STAT6-mediated induction of chemokines ⁶⁶ STING mediated induction of host immune responses ⁶⁶ ZBP1(DAI) mediated induction of type I IFNs ⁶⁶	12.37	TLR3 IFNB1 IFNA6 IFNA1
16	Diseases of Immune System ⁶⁶ Show member pathways Diseases associated with the TLR signaling cascade ⁶⁶ Endogenous TLR signaling ⁶¹ IRAK4 deficiency (TLR2/4) ⁶⁶ IRAK4 deficiency (TLR5) ⁶⁶ MyD88 deficiency (TLR2/4) ⁶⁶ MyD88 deficiency (TLR5) ⁶⁶ Regulation of TLR by endogenous ligand ⁶⁶ Toll-like receptor signaling related to MyD88 ⁷⁴ Transfer of LPS from LBP carrier to CD14 ⁶⁶	12.22	TLR9 TLR8 TLR7 TLR4 TLR3
17	Colorectal Cancer Metastasis ⁶⁴	12.15	TP53 TLR9 TLR8 TLR7 TLR4 TLR3
18	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.09	TP53 IL2 IFNB1 CDKN2A CD8A CD4
19	Integrin family cell surface interactions ⁶¹ Show member pathways Phagocytosis of Microbes ⁶⁴ Plexin-D1 Signaling ⁶¹	12.08	TLR3 TLR4 TLR7 TLR8 TLR9
20	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	12	NCR1 IL2 GP5 CD8A CD4
21	Host-pathogen interaction of human coronaviruses - interferon induction ⁷⁴ Show member pathways Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics ⁶⁰ SARS coronavirus and innate immunity ⁷⁴ Type I interferon induction and signaling during SARS-CoV-2 infection ⁷⁴	11.9	TLR9 TLR7 TLR4 TLR3 IFNB1
22	Interferon Pathway ⁶⁴	11.81	IFNB1 IFNA6 IFNA1
23	Innate Lymphoid Cells Differentiation ⁶⁵	11.81	NCR1 IL2 CD8A CD4 CCR6
24	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	11.78	TP53 TLR9 TLR8 TLR7 TLR4 TLR3
25	Acute viral myocarditis ⁷⁴	11.76	TLR4 TLR3 IL2 CD4
26	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.76	TLR9 TLR8 TLR7 TLR4 TLR3 CD4
27	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.74	IFNB1 CD8A CD4
28	Burn wound healing ⁷⁴	11.72	TP53 TLR4 IFNB1
29	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.69	TLR7 TLR4 IL2
30	AP-1 transcription factor network ⁶¹	11.68	TP53 IL2 CDKN2A
31	miRNAs involvement in the immune response in sepsis ⁷⁴	11.63	TLR8 TLR7 TLR4
32	Prader-Willi and Angelman syndrome ⁷⁴	11.61	UBE3A TP53 CDKN2A
33	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.6	CD4 CD8A IFNB1 IL2 TLR7 TLR9
34	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.5	TLR8 TLR7 TLR4
35	Fibrin complement receptor 3 signaling pathway ⁷⁴	11.45	TLR4 TLR3 IFNB1
36	Kynurenine pathway and links to cell senescence ⁷⁴ Show member pathways Tryptophan catabolism ⁶⁶	11.36	TP53 TLR4 IFNB1
37	Cytokines and inflammatory response ⁷⁴	11.25	IL2 IFNB1 CD4
38	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.17	TLR9 TLR8 TLR7 TLR4 TLR3 IL2
39	mRNA vaccine activation of dendritic cell and induction of IFN-1 ⁷⁴	10.73	TLR8 TLR7 TLR3

Sources

GO Terms for Anogenital Venereal Wart

Cellular components related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016021	10.29	CCR6 CD4 CD8A GP5 GP6 NCR1
2	membrane	GO:0016020	10.29	CCR6 CD4 CD8A GP5 GP6 NCR1
3	plasma membrane	GO:0005887	10.03	CCR6 CD4 CD8A GP5 GP6 NCR1
4	plasma membrane	GO:0005886	10.03	CCR6 CD4 CD8A GP5 GP6 NCR1
5	endosome membrane	GO:0010008	9.96	TLR9 TLR8 TLR7 TLR4 TLR3
6	endolysosome membrane	GO:0036020	9.23	TLR9 TLR8 TLR7 TLR3

Biological processes related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

(show all 35)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.57	UBE3A TP53 TLR9 TLR7 TLR4 TLR3
2	adaptive immune response	GO:0002250	10.43	IL2 IFNB1 IFNA6 IFNA1 CD8A CD4
3	immune response	GO:0006955	10.34	TLR9 TLR7 TLR4 TLR3 IL2 CD8A
4	defense response to virus	GO:0051607	10.28	IFNA1 IFNA6 IFNB1 TLR3 TLR7 TLR8
5	positive regulation of inflammatory response	GO:0050729	10.26	IL2 TLR3 TLR4 TLR7 TLR9
6	positive regulation of interleukin-6 production	GO:0032755	10.25	TLR9 TLR8 TLR7 TLR4 TLR3
7	cellular response to mechanical stimulus	GO:0071260	10.21	TLR8 TLR7 TLR4 TLR3
8	cellular response to virus	GO:0098586	10.21	IFNA1 IFNA6 IFNB1 TLR3 TLR7
9	positive regulation of NIK/NF-kappaB signaling	GO:1901224	10.19	TLR3 TLR4 TLR7 TLR9
10	humoral immune response	GO:0006959	10.19	IFNB1 IFNA6 IFNA1 CCR6
11	positive regulation of interleukin-8 production	GO:0032757	10.18	TLR9 TLR8 TLR7 TLR4 TLR3
12	positive regulation of chemokine production	GO:0032722	10.17	TLR9 TLR7 TLR4 TLR3
13	positive regulation of B cell proliferation	GO:0030890	10.14	TLR9 TLR4 IL2
14	positive regulation of interleukin-12 production	GO:0032735	10.14	TLR9 TLR4 TLR3
15	type I interferon-mediated signaling pathway	GO:0060337	10.14	IFNB1 IFNA6 IFNA1
16	response to exogenous dsRNA	GO:0043330	10.14	IFNA1 IFNA6 IFNB1 TLR3
17	response to virus	GO:0009615	10.13	TLR9 TLR8 TLR3 IFNB1
18	B cell proliferation	GO:0042100	10.12	TLR4 IFNB1 IFNA6 IFNA1
19	natural killer cell activation	GO:0030101	10.11	NCR1 IL2 IFNB1
20	T cell activation involved in immune response	GO:0002286	10.1	IFNA1 IFNA6 IFNB1
21	positive regulation of macrophage cytokine production	GO:0060907	10.1	TLR3 TLR4 TLR7
22	immune system process	GO:0002376	10.1	TLR9 TLR8 TLR7 TLR4 TLR3 IL2
23	positive regulation of peptidyl-serine phosphorylation of STAT protein	GO:0033141	10.09	IFNB1 IFNA6 IFNA1
24	MyD88-dependent toll-like receptor signaling pathway	GO:0002755	10.09	TLR9 TLR8 TLR4
25	natural killer cell activation involved in immune response	GO:0002323	10.08	IFNB1 IFNA6 IFNA1
26	I-kappaB kinase/NF-kappaB signaling	GO:0007249	10.06	TLR9 TLR8 TLR7 TLR4 TLR3
27	positive regulation of type II interferon production	GO:0032729	10.03	IL2 TLR3 TLR4 TLR7 TLR8 TLR9
28	positive regulation of interferon-beta production	GO:0032728	10.02	TLR9 TLR8 TLR7 TLR4 TLR3
29	I-kappaB phosphorylation	GO:0007252	9.97	TLR9 TLR7 TLR4 TLR3
30	defense response	GO:0006952	9.95	IFNA1 IFNA6 IFNB1 TLR3
31	positive regulation of toll-like receptor signaling pathway	GO:0034123	9.94	TLR9 TLR3
32	regulation of dendritic cell cytokine production	GO:0002730	9.88	TLR9 TLR4 TLR3
33	positive regulation of interferon-alpha production	GO:0032727	9.85	TLR9 TLR8 TLR7 TLR4 TLR3
34	toll-like receptor signaling pathway	GO:0002224	9.61	TLR9 TLR8 TLR7 TLR4 TLR3
35	response to external stimulus	GO:0009605	9.02	TLR9 TLR8 TLR7 TLR4 TLR3

Molecular functions related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	pattern recognition receptor activity	GO:0038187	9.73	TLR9 TLR8 TLR7
2	signaling receptor activity	GO:0038023	9.73	CCR6 CD4 GP6 TLR3 TLR4 TLR8
3	type I interferon receptor binding	GO:0005132	9.63	IFNB1 IFNA6 IFNA1
4	cytokine receptor binding	GO:0005126	9.62	IFNB1 IFNA6 IFNA1
5	transmembrane signaling receptor activity	GO:0004888	9.47	TLR9 TLR8 TLR7 TLR4 TLR3 GP6